Unlock instant, AI-driven research and patent intelligence for your innovation.

siRNA for inhibiting MCM7, composition and application of siRNA

A composition and drug technology, applied in the field of biomedicine, can solve problems such as siRNA that have not yet been seen, achieve significant clinical application prospects and economic value, improve efficiency, and improve therapeutic effects

Pending Publication Date: 2021-03-05
ENKANG PHARMA GUANGZHOU LTD +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the siRNA used to inhibit the MCM7 gene of cancer cells such as liver cancer, gastric cancer, and prostate cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • siRNA for inhibiting MCM7, composition and application of siRNA
  • siRNA for inhibiting MCM7, composition and application of siRNA
  • siRNA for inhibiting MCM7, composition and application of siRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Example 1 siRNA design

[0072] According to the basic principle of siRNA target sequence, the siRNA sequence (1 21 nucleotides) expressed by the human MCM7 gene transcript (NM_001278595.1) was designed and synthesized, that is, the sense strand and the antisense strand of siRNA, and its base sequence is:

[0073] siRNA-1 sense strand: 5'-GGACUUAAUUUGUGAGAAUdTdT-3'; (SEQ ID NO.1)

[0074] siRNA-1 antisense strand: 5'-AUUCUCACAAAUUGAGUCCdTdT-3' (SEQ ID NO.2).

[0075] or

[0076] siRNA-2 sense strand: 5'-GGAAGUGGUAAAUAAAGAUdTdT-3' (SEQ ID NO.3);

[0077] siRNA-2 antisense strand: 5'-AUCUUUAUUUACCACUUCCdTdT-3' (SEQ ID NO.4).

[0078] The base sequence of the negative control RNA (NC) is:

[0079] Sense strand: 5'-CUCUUAGCCAAUAUUCGCUdTdT-3' (SEQ ID NO.5);

[0080] Antisense strand: 5'-AGCGAAUAUUGGCUAAGAGdTdT-3' (SEQ ID NO. 6).

[0081] The siRNA sequence of the present invention and the 3' end of the sense strand and the antisense strand of the control RNA are added ...

Embodiment 2

[0084] Example 2 Transfection of siRNA in cells

[0085] The liposome Lipofectamine RNAiMax was used as the transfection reagent, and the steps were in accordance with the operating procedures of Thermo Fisher Scientific Company. The cell lines used were HepG2 and Hep3B liver cancer cell lines, SGC-7907 gastric cancer cell line, PC3 prostate cancer cell line and MCF7 breast cancer cell line.

[0086] The experimental method of the present invention not indicating specific conditions, generally according to conventional conditions such as the conditions described in "Molecular Cloning: Laboratory Guide" (New York: Cold Spring Harbor Laboratory Press, 1989) by Sambrook et al. suggested conditions.

[0087] The transfection steps are as follows: inoculate the above-mentioned different cell lines in 12-well plates, culture overnight at 37° C. and 5% CO 2 , so that the cell growth density reaches 40-50%. Referring to the operating procedure of Lipofectamine RNAiMax (Thermo Fisher...

Embodiment 3

[0088] Example 3 siRNA inhibits MCM7mRNA expression detection

[0089] Methods: Cells were collected after transfection, total RNA was extracted, and real-time fluorescent quantitative PCR was performed after reverse transcription to detect the expression of MCM7mRNA after siRNA treatment of cancer cells.

[0090] The siRNA prepared by the present invention and the negative control RNA (NC) were respectively transfected into the liver cancer cell line HepG2, and the same method was also used to transfect the liver cancer cell line Hep3B. After 24 hours of transfection, the cells were collected, and an appropriate amount of cells were re-inoculated in In 6-well plates, cells were harvested after 72 hours to extract total RNA. Reverse transcription, and real-time fluorescent quantitative PCR detection of MCM7mRNA.

[0091] 1. Total RNA Extraction

[0092] (1) Collect tumor cells into centrifuge tubes, centrifuge at 800rpm for 3min, discard supernatant, add PBS to wash once and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses siRNA for inhibiting MCM7, a composition and an application of the siRNA. The siRNA designed and verified by the invention can efficiently inhibit MCM7 gene expression so as toinhibit DNA synthesis cell proliferation and cell clone generation of cancer cells, and the purpose of preventing and treating tumors is achieved. The invention provides a new target and candidate drug for preventing or treating cancers.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to siRNA for inhibiting MCM7, composition and application thereof. Background technique [0002] The MCM complex is composed of MCM2~MCM7 subunits, has helicase activity in the cell, opens the DNA double strand before DNA replication, and participates in the initiation of DNA replication (Bik Tye, Annual Review of Biochemistry, 1999). Moreover, the MCM complex also plays an important regulatory role in cell proliferation, DNA damage repair and cell cycle. [0003] Small interfering RNA (Small interfering RNA, siRNA) is a double-stranded RNA with a length of 20-25 nucleotides. It was first discovered in the phenomenon of post-transcriptional gene silencing in plants. It has been publicly reported that artificially synthesized siRNA can silence mammalian cells specific gene expression (Thomas Tuschl et al., Nature, 2001; Thomas Tuschl et al., Science, 2001; Thomas Tuschl et al., Cell, 2002...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K31/713A61P35/00
CPCA61P35/00C12N15/1137C12N2310/14C12Y306/04012A61K31/713C07H21/02C12N15/10C12N15/113
Inventor 梁纯王俊张文熙
Owner ENKANG PHARMA GUANGZHOU LTD